Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs
Open accessAbstract
This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The success of ICI therapy is dependent on factors such as the expression of immune checkpoint markers (i.e., PD-L1, CTLA-4 and LAG3) by the tumor cells, the TME, and the infiltration of functional, tumor-killing cytotoxic T cells.
“as the success of this therapy is dependent on various factors such as the expression of immune checkpoint markers (i.e., PD-L1, CTLA-4 and LAG3) by the tumor cells, the TME and the infiltration of functional, tumor-killing cytotoxic T cells (Bonaventura et al., 2019a; Haslam et al., 2020; Wang et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Haslam et al., 2020
The Methods section links PD-L1 status to ICI eligibility, noting an approval for PD-L1-positive patients with triple-negative breast cancer and a response-rate difference. It does not address CTLA-4, LAG3, the tumor microenvironment, or infiltration by functional cytotoxic T cells as factors in treatment success. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · see citing works
Self-citationA reality check of the accelerated approval of immune-checkpoint inhibitors
Gill, J., & Prasad, V. K. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0260-y · Cited by 43 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 12 · see citing works
“…of this therapy is dependent on various factors such as the expression of immune checkpoint markers (i.e., PD-L1, CTLA-4 and LAG3) by the tumor cells, the TME and the in fi ltration of functional, tumor-killing cytotoxic T cells (Bonaventura et al., 2019a; Haslam et al., 2020; Wang et al., 2023).”
Background
- Authors
- Haslam, A., Gill, J., & Prasad, V.
- Affiliations
- Oklahoma State University (US)
- Oregon Health & Science University (US)
- Corresponding author
- Haslam, Alyson
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-03-09
- Volume
- 3
- Issue
- 3
- Pages
- e200423
- ISSN
- 2574-3805 (ISSN-L)
- PMC
- PMC7063495
- OpenAlex
- W3010374810
- Cited by
- 283
- References
- 2
- Citations by year
- 2026: 30 · 2025: 63 · 2024: 55 · 2023: 56 · 2022: 38 · 2021: 31 · 2020: 9
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- JAMA Network Open (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- immune checkpoint inhibitors, cancer patients, eligibility, treatment eligibility, immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Cross-Sectional Studies, Drug Labeling, Eligibility Determination, Humans, Neoplasms, Practice Patterns, Physicians', Product Surveillance, Postmarketing, United States, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
